Parkinson’s Disease

Mhyre, Timothy R.; Boyd, James T.; Hamill, Robert W.; Maguire‐Zeiss, Kathleen A.

doi:10.1007/978-94-007-5416-4_16

Cited by 335 publications

(222 citation statements)

References 423 publications

(531 reference statements)

Supporting

Mentioning

203

Contrasting

Unclassified

Order By: Relevance

“…It greatly affects the quality of life of patients (Zhang et al, 2016). Incidence of PD disease is approximately 1.8 times higher in men versus women (1.5-2.0) (Hirtz et al 2007;Mhyre, et al, 2012). The study of Zhang et al, 2016 revealed that the incidence of PD is slightly higher in males than in females; the ratio was close to 1:1, the average age of PD patients was about 60 years, the education level of patients with PD was paralleled with that of age-matched (40-70 years old) (Ransmayr, 2015), and education is not an associated factor for PD.…”

Section: Introductionmentioning

confidence: 99%

“…The study of Zhang et al, 2016 revealed that the incidence of PD is slightly higher in males than in females; the ratio was close to 1:1, the average age of PD patients was about 60 years, the education level of patients with PD was paralleled with that of age-matched (40-70 years old) (Ransmayr, 2015), and education is not an associated factor for PD. The socioeconomic burden of PD is great with estimates of both direct and indirect costs upward of about $23 billion every year in the US (Huse et al 2005;Mhyre, et al, 2012). Age is the single greatest risk factor for PD with the number of world-wide cases increasing from an estimated 4.1 million (340,000 US cases) in 2005 to nearly 8.7 million (610,000 US cases) by 2030 (Dorsey et al 2007;Mhyre, et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

“…The socioeconomic burden of PD is great with estimates of both direct and indirect costs upward of about $23 billion every year in the US (Huse et al 2005;Mhyre, et al, 2012). Age is the single greatest risk factor for PD with the number of world-wide cases increasing from an estimated 4.1 million (340,000 US cases) in 2005 to nearly 8.7 million (610,000 US cases) by 2030 (Dorsey et al 2007;Mhyre, et al, 2012). Whites have a substantially higher prevalence and incidence of Parkinson disease than Blacks or Asians (Willis et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Enwerem¹,

Okunji²,

Ngwa³

et al. 2018

IJSN

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) is the second most common neurodegenerative disease, after Alzheimer's disease, affecting approximately one million persons aged 65 years and above in the United States. Parkinson's disease represents a major medical concern for health professionals, national healthcare bodies and a heavy burden for caregivers. Heart failure occurred twice as frequently in elderly PD patients as in non-PD patients. There is paucity of information on the association of patient and hospital characteristics on the outcomes of inpatient with both congestive heart failure and Parkinson disease.Congestive Heart Failure with PD as a comorbidity will increase the cost of care and health resources. We investigate on the current prevalence and factors that affect the inpatient with both CHF and PD conditions using a longitudinal datasets from National Inpatient Samples. The results obtained from this study will provide information that will reduce frequent readmission, length of stay, total charges and mortality rate in this population.Methods: Data from the National Inpatient Samples (NIS) were extracted and analyzed using ICD 9 codes (CHF 428, PD 332) for the main diagnosis. For continuous variables, we calculated the mean and standard deviations and evaluated significant differences of these factors by Parkinson disease status using the t-test. For categorical variables, we obtained the counts (proportions) and evaluated significant differences using the Chi-square and Fisher's exact test Propensity score was utilized to match age, gender and race using logistic model for hospital death and generalized linear model for length of stay (LOS) and hospital charges.Result: The overall frequency of Parkinson disease (PD) in congestive heart failure was 1.54 % (n = 10,748). PD patients with CHF were more likely to be males (53.13 %; 5462) and Caucasians (82.24 %; n=8454). The average age of inpatient was approximately 80 years (SD=8.05). Hospital admission, decreases with median household income. Patients with low income ($1 -$38,999) were admitted more with 3002 (29.70%) than those with higher income ($63,000 and more) with 2230 (22.06%). Length of stay (LOS) (p<0.0001) and total charge incurred during hospitalization were less in patients with PD (p< 0.005) (table 1). In these analyses, we found that patients with PD were discharged more from urban non-teaching hospital than urban teaching hospital (p<0.0001).Conclusion: The general characteristics and frequency of the participant in this study are summarized in Table I. Accordingly, characteristics of patients with congestive heart failure with or without Parkinson's disease did not differ by age, gender, or ethnicity (P>1.000). Similarly, hospital death rates (%) were not different (P>1.000), although hospital length of stay (P<1.000) and total charge incurred during hospitalization were less in patients with PD (p < 0.005)

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Enwerem¹,

Okunji²,

Ngwa³

et al. 2018

IJSN

View full text Add to dashboard Cite

show abstract

“…Characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. [4] The pathological hallmark of the illness is a relatively selective degeneration of the neuromelanin-pigmented dopaminergic neurons of the substantia nigra pars compacta coupled with the formation of intracytoplasmic protein aggregates known as Lewy bodies. [5,6] Progressive loss of dopaminergic neurons is a feature of normal aging; however, symptoms of PD coincide with excessive loss (70-80%) of these neurons.…”

mentioning

confidence: 99%

Untitled

Aamir¹

2017

IJGP

View full text Add to dashboard Cite

Aim: The objectives of the present research were ssto observe the effect of N-methyl-D-aspartate (NMDA) receptor antagonist on Parkinson model(s) in rats and to compare the efficacy of NMDA receptor antagonist with standard antiparkinson drug. Materials and Methods: Albino rats were divided into five experimental groups of six each. 24 animals except normal and acute dose of haloperidol (1 mg/kg) were administered intraperitoneally for induction of catalepsy. Six animals received saline 0.9% NaCl and served as normal saline. On the 20 th day, catalepsy was evaluated by reported instruments. Levodopa (150mg/kg) was used as standard drug and kynurenic acid (50 mg/kg and 100 mg/kg) was used as test drug. Different instrument utilized in the study was catalepsy bar test, actophotometer, and rotarod. Results and Discussions: The results showed that acute administration of kynurenic acid (50 mg/kg and 100 mg/kg) significantly reduced catalepsy, grooming and significantly increased motor coordination, locomotor activity. Conclusion: It was concluded from the study that kynurenic acid ameliorates the symptoms of Parkinson's disease in rats.

show abstract

“…Mutation of parkin was associated with Parkinson's disease [5]. PINK1 drives parkin to locate in mitochondria and interacts with each other to promote mitophagy.…”

Section: Introductionmentioning

confidence: 99%

Parkin Modulates ERRα/eNOS Signaling Pathway in Endothelial Cells

Xia

Yin

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Although a number of reports documented the important role of parkin in mitophagy, emerging evidence also indicated additional functions of parkin besides mitophagy. The present study was undertaken to investigate the role of parkin in the regulation of ERRα/eNOS pathway in endothelial cells (ECs). Methods: Mouse aortic endothelial cells (MAECs) and cardiac muscle HL-1 cells were transfected with parkin plasmid or siRNA. ERRα inhibitor XCT-790, autophagy inhibitor 3-MA and Bafilomycin A1, and caspase inhibitor Z-VAD-FMK were used to block autophagy or apoptosis. Western blotting was performed to examine the protein levels. Flow cytometry was applied to determine the cell apoptosis and ROS production. Mitochondrial membrane potential was measured using JC-1 and TMRM. Immunoprecipitation was performed to confirm the parkin effect on ERRα ubiquitination. Results: Overexpression of parkin resulted in a significant reduction of total-eNOS and p-eNOS in parallel with the downregulation of ERRα (a regulator of eNOS) protein and the enhancement of ERRα ubiquitination. To test the role of ERRα in regulating eNOS in this experimental setting, we treated ECs with ERRα inhibitor and found a decrement of total-eNOS and p-eNOS. On the contrary, overexpression of ERRα increased the levels of total-eNOS and p-eNOS. Meanwhile, parkin overexpression induced mitochondrial dysfunction and cell apoptosis in both ECs and HL-1 cells. Finally, we confirmed that the parkin effect on the regulation of eNOS was independent of the autophagy and apoptosis. Conclusion: These findings suggested that parkin overexpression downregulated eNOS possibly through the ubiquitination of ERRα in endothelial cells.

show abstract

Parkinson’s Disease

Cited by 335 publications

References 423 publications

Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Prevalence of Parkinson Disease in Hospitalized Patients With Congestive Heart Failure

Untitled

Parkin Modulates ERRα/eNOS Signaling Pathway in Endothelial Cells

Contact Info

Product

Resources

About